Geron (NASDAQ:GERN) Shares Up 4.6%

Geron Co. (NASDAQ:GERN) shares traded up 4.6% during mid-day trading on Wednesday . The stock traded as high as $3.71 and last traded at $3.66. 2,995,182 shares were traded during trading, a decline of 73% from the average session volume of 11,080,196 shares. The stock had previously closed at $3.50.

Analyst Upgrades and Downgrades

GERN has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price target on shares of Geron in a report on Thursday, April 11th. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Geron in a report on Wednesday, April 10th. Finally, The Goldman Sachs Group upped their price objective on shares of Geron from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Friday, March 15th.

Geron Trading Up 2.3 %

The firm has a market cap of $1.96 billion, a P/E ratio of -10.85 and a beta of 0.62. The business’s fifty day moving average is $2.80 and its 200-day moving average is $2.27. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.16 and a current ratio of 3.16.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. During the same period in the previous year, the company posted ($0.10) EPS. The firm’s revenue was down 77.7% compared to the same quarter last year. Analysts predict that Geron Co. will post -0.34 EPS for the current year.

Institutional Investors Weigh In On Geron

Institutional investors and hedge funds have recently made changes to their positions in the business. Pathstone Family Office LLC bought a new stake in Geron in the 3rd quarter worth about $26,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Geron by 101.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,757 shares during the period. Federated Hermes Inc. purchased a new position in Geron in the third quarter valued at approximately $29,000. SG Americas Securities LLC bought a new position in Geron during the third quarter valued at $40,000. Finally, Twin Peaks Wealth Advisors LLC purchased a new stake in Geron in the fourth quarter worth $58,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.